Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | CCR1 | P32246 | 2/20 | 0.65 |
| ▸ | CCR5 | P51681 | 2/20 | 0.65 |
| ▸ | CCR8 | P51685 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | METAP1 | P53582 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.65 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 8/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10756432 | 1.00 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| Benzene SCHEMBL29224585 | 0.97 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28062312 | 0.97 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL35754 | 0.97 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL29360780 | 0.97 | KDM4E (0.68) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL608973 | 0.95 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL609602 | 0.95 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL7764586 | 0.95 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL16868474 | 0.95 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL140400 | 0.95 | KDM4E (0.65) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2762467-B1 | Method for producing an optically active 2-arylpiperidinium salt | TAKASAGO PERFUMERY CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9012649-B2 | Method for producing optically active 2-arylpiperidinium salt | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2762467-A1 | Method for producing an optically active 2-arylpiperidinium salt | Takasago International Corporation (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213792-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERIDINIUM SALT | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213792-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-ARYLPIPERIDINIUM SALT | REN, KCNH3, KCNH2 | KDM4E 2931/4885LMNA 4810/4885CCR1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.